Navigation Links
Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
Date:3/29/2013

sprinolactone/diuretics, and biventricular pacing devices. No treatment substitution decision is required by the treating physician. A recent Phase 2 clinical trial demonstrated sustained improvement at one year in cardiac function parameters and quality of life. A 200 patient Phase 2b study of MYDICAR was initiated in August 2012.

About the CUPID Phase 2b Trial

The CUPID Phase 2b trial was initiated in August 2012 and will enroll approximately 200 patients in up to 50 sites worldwide.  Patients will first be prescreened for the presence of AAV neutralizing antibodies. Those patients with a negative titer will undergo further screening tests and procedures to determine eligibility prior to randomization and enrollment into the study. All patients will be randomized in parallel to MYDICAR or placebo in a ratio of 1:1 (1 x 1013 DRP MYDICAR to placebo).

The primary objective is to determine the efficacy of MYDICAR in patients with ischemic or dilated cardiomyopathy and NYHA class III/IV symptoms of HF by reducing the frequency and/or delaying HF-related hospitalizations compared to placebo-treated patients.

The primary efficacy endpoint is time-to-recurrent HF-related hospitalizations in the presence of terminal events (all-cause death, heart transplant, LVAD implantation). The secondary efficacy endpoint is the time-to-terminal event (all-cause death, heart transplant, LVAD implantation). Exploratory endpoints include change from baseline in NYHA class, 6 minute walk test distance, and quality of life (KCCQ) score.

Secondary objectives will include assessment of the safety of MYDICAR by determining the incidence and severity of adverse events and changes in laboratory parameters. Safety evaluations include the incidence and severity of all adverse events (including procedure-related), summaries of concomitant medications, vital signs, physical exams, implantable cardioverter defibrillator (ICD) interrogations and la
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
3. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
4. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
5. Neogen Corporation Announces 2nd Quarter Results Conference Call
6. Luminex Corporation to Present at JP Morgan Healthcare Conference
7. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
8. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
9. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... Graphite Metallizing Corporation, the ... announces the appointment of Dennis Rawle as European Director of Sales. Rawle has ... he was General Manager and Technical Sales Manager for pump products at Exalto ...
(Date:8/4/2015)... 2015 According to a ... "World Cardiac Biomarker - Market Opportunities, and Forecast, ... the revenue of $2,085.9 million by 2020, registering ... Cardiac Troponins (T, I) would continue to dominate ... high sensitivity and specificity.      (Logo: ...
(Date:8/4/2015)... Calif. , Aug. 4, 2015 Trigemina, ... development of non-narcotic, nasally delivered, analgesic drug products, announced ... M.D., to the position of chief medical officer. Dr. ... to Trigemina, much of which has been focused in ... thrilled to add Dr. Kori to our clinical team ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... of rapid point-of-care (POC) diagnostic tests – today announced that Robert A. Gregg, ... Dr. Gregg has more than 30 years of relevant experience and remarkable achievements ...
Breaking Biology Technology:Dennis Rawle Joins Graphite Metallizing Corporation 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 2Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 3Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 4Cardiac Biomarker Market is Expected to Reach $2,085.9 Million by 2020 5Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3
... for friends, fun, fantasy, fortune or fame has become ... From the Korean social networking site Cyworld, to the ... originator Classmates (according to Wikipedia ), ... social networking sites are filling a void in the ...
... second consecutive year, the City of Madison received ... municipalities in the country. , ,In its 2006 Digital ... national research and advisory institute on information technology and best ... the top user of technology in its 125,000-249,999 population category. ...
... Editor's note: This is the first in a three-part series ... WTN Media's Boardroom Perspectives column, are written by associates in ... , , Which pieces of information systems ... idea, we recently completed an analysis of material weaknesses reported ...
Cached Biology Technology:Virtual communities make online connections 2Virtual communities make online connections 3Virtual communities make online connections 4Virtual communities make online connections 5Virtual communities make online connections 6Auditors paying more attention to IT woes 2Auditors paying more attention to IT woes 3
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... 2008Once believed to be important only for bone health, ... function in maintaining the immune system throughout life. The ... are clearly documented in a report in the December ... , a peer-reviewed journal published by Mary Ann Liebert, ...
... astronomy Apparao Rao has been named a Fellow of ... peers for outstanding contributions to physics. Fellowship is limited ... of the membership. Rao was recognized for developing ... properties of carbon nanotubes through Raman spectroscopy, a technique ...
... FASEB Journal shows that the equivalent of one dose ... may be enough to affect fetal heart development and then ... In addition, the researchers also found that this relatively minimal ... males, when compared to those who were not exposed to ...
Cached Biology News:Vitamin D deficiency in infants and nursing mothers carries long-term disease risks 2A low dose of caffeine when pregnant may damage the heart of offspring for a lifetime 2
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
NAP-2 (5C7)...
... advanced RACE (rapid amplification of cDNA ends) ... full-length 5' and 3' cDNA ends. The ... Reverse Transcriptase (RT) for improved amplification of ... complex mRNA. The RNase H portion of ...
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: